U.S. FDA Approves GlaxoSmithKline Antiretroviral Drug Dolutegravir
August 13, 2013
The FDA on Monday approved GlaxoSmithKline's antiretroviral dolutegravir, an integrase strand transfer inhibitor "that was developed by ViiV Healthcare Ltd., its joint venture with two other drugmakers," Bloomberg reports (Edney, 8/12). "The pill is taken daily in combination with others and can be prescribed to patients who have never taken therapy before, as well as those that have," The Hill's "RegWatch" blog notes (Hattem, 8/12). The drug, known under the brand name Tivicay, "was tested in adults in four clinical trials in combination with other antiretroviral drugs, and in one trial involving children," according to Reuters (8/12).
This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily Global Health Policy Report. Visit the Kaiser Family Foundation's website to find out more about their activities, publications and services.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)